Andras Heczey, MD, on Antitumor Activity of CAR NKTs in Solid Tumors


The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.

"With natural killer T-cells, or NK T cells for short, we have the ability to use a homogeneous population of effector lymphocytes that are able to effectively traffic into the tumor sites better than just conventional T cells... They can recognize cancer supportive tumor associated macrophages... and specifically target them. So that provides a big opportunity for NK T cell-based therapeutics to make a major impact in the treatment of solid tumor patients.”

Chimeric antigen receptor (CAR) natural killer (NK) T-cell therapy is well-tolerated with promising responses in patients with neuroblastoma, according to data from a phase 1 study (NCT03294954) presented by Andras Heczey, MD, Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine at the American Society of Gene & Cell Therapy 25th Annual Meeting (ASGCT), held in Washington, DC, and virtually May 16-19, 2022.

Heczey and colleagues found that antitumor activity was associated with dosage and in vivo rate of expansion after treating 12 patients in 4 dose levels of 3x106 CAR+ NKTs/m2, 1x107 CAR+ NKTs/m2, 3x107 CAR+ NKTs/m2, and 1x108 CAR+ NKTs/m2 following lymphodepletion. Of these patients, 5 had progressive disease, 4 had stable disease, 2 had a partial response, and 1 had a complete response. No dose limiting toxicities or serious toxicities related to treatment were observed.

CGTLive spoke with Heczey to learn more about the phase 1 study and trends observed with antitumor activity. He discussed challenges with treating solid tumors and more research to be done.

Herczey A, Courtney A, Ghatwai N, et al. Anti-GD2 CAR NKT cells are safe and produce antitumor responses in patients with relapsed/refractory neuroblastoma. Presented at ASGCT 25th Annual Meeting May 16-19, 2022, Washington DC. Abstract #54
Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.